|
|
||||||||
From the Departments of Neurology (Drs. Pearl, Acosta, Gropman, and Conry), Radiology (Dr. Vezina), and Metabolism (Drs. Gropman, Berry, and Tuchman), Childrens National Medical Center, George Washington University School of Health Sciences, Washington, DC; Departments of Molecular and Medical Genetics, and Pediatrics (Dr. Gibson), Oregon Health Sciences University, Portland; Epilepsy Research Branch (Drs. Theodore and Rogawski), NINDS, NIH, Bethesda, MD; and Yale University School of Medicine (Dr. Novotny), New Haven, CT.
Address correspondence and reprint requests to Dr. Phillip L. Pearl, Department of Neurology, Childrens National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010-2970; e-mail: ppearl{at}cnmc.org
Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare autosomal recessive disorder affecting CNS
-aminobutyric acid (GABA) degradation. SSADH, in conjunction with GABA transaminase, converts GABA to succinate. In the absence of SSADH, GABA is converted to 4-OH-butyrate. The presence of 4-OH-butyrate, a highly volatile compound, may be undetected on routine organic acid analysis. Urine organic acid testing was modified at the authors institution in 1999 to screen for the excretion of 4-OH-butyrate by selective ion monitoring gas chromatography-mass spectrometry in addition to total ion chromatography. Since then, five patients with 4-hydroxybutyric aciduria have been identified. The authors add the clinical, neuroimaging, and EEG findings from a new cohort of patients to 51 patients reported in the literature with clinical details. Ages ranged from 1 to 21 years at diagnosis. Clinical findings include mild-moderate mental retardation, disproportionate language dysfunction, hypotonia, hyporeflexia, autistic behaviors, seizures, and hallucinations. Brain MRI performed in five patients at the authors institution revealed symmetric increased T2 signal in the globus pallidi. SSADH deficiency is an under-recognized, potentially manageable neurometabolic disorder. Urine organic acid analysis should include a sensitive method for the detection of 4-hydroxybutyrate and should be obtained from patients with mental retardation or neuropsychiatric disturbance of unknown etiology.
This article has been cited by other articles:
![]() |
P. L. Pearl, K. M. Gibson, Z. Quezado, I. Dustin, J. Taylor, S. Trzcinski, J. Schreiber, K. Forester, P. Reeves-Tyer, C. Liew, et al. Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency Neurology, August 11, 2009; 73(6): 423 - 429. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Allan, J. P. Simpson, S. M. Clark, and B. J. Shelp {gamma}-Hydroxybutyrate accumulation in Arabidopsis and tobacco plants is a general response to abiotic stress: putative regulation by redox balance and glyoxylate reductase isoforms J. Exp. Bot., June 1, 2008; 59(9): 2555 - 2564. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Marchitti, R. A. Deitrich, and V. Vasiliou Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase Pharmacol. Rev., June 1, 2007; 59(2): 125 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. Pearl, J. L. Taylor, S. Trzcinski, and A. Sokohl The Pediatric Neurotransmitter Disorders J Child Neurol, May 1, 2007; 22(5): 606 - 616. [Abstract] [PDF] |
||||
![]() |
N. C. Schanen Epigenetics of autism spectrum disorders Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R138 - R150. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gonzalez and D. J. Nutt Gamma hydroxy butyrate abuse and dependency J Psychopharmacol, March 1, 2005; 19(2): 195 - 204. [Abstract] [PDF] |
||||
![]() |
T. Ethofer, U. Seeger, U. Klose, M. Erb, B. Kardatzki, E. Kraft, G. B. Landwehrmeyer, W. Grodd, and A. Storch Proton MR spectroscopy in succinic semialdehyde dehydrogenase deficiency Neurology, March 23, 2004; 62(6): 1016 - 1018. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |